These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10701150)

  • 1. How to do without steroids in inflammatory bowel disease.
    Present DH
    Inflamm Bowel Dis; 2000 Feb; 6(1):48-57; discussion 58. PubMed ID: 10701150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.
    Campieri M
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III43-6. PubMed ID: 11953332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
    Gross V
    Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review and update on Crohn's disease.
    Gajendran M; Loganathan P; Catinella AP; Hashash JG
    Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Classical medications in the treatment of inflammatory bowel diseases].
    Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
    Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy of inflammatory bowel disease.
    Rutgeerts P
    Digestion; 1998 Aug; 59(5):453-69. PubMed ID: 9705531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacotherapy of inflammatory bowel disease].
    Jojić N
    Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.
    Hawthorne AB; Hawkey CJ
    Drugs; 1989 Aug; 38(2):267-88. PubMed ID: 2670519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how.
    Prantera C; Scribano ML
    Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.
    Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M
    Eur Rev Med Pharmacol Sci; 1999; 3(1):27-30. PubMed ID: 10710827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing therapy for inflammatory bowel disease.
    Robinson M
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.
    Fedorak RN; Ismond KP
    Dig Dis; 2016; 34(1-2):112-21. PubMed ID: 26982586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management.
    Kerman DH; Deshpande AR
    Postgrad Med; 2014 Jul; 126(4):7-19. PubMed ID: 25141239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of antibiotics for treatment of inflammatory bowel disease.
    Nitzan O; Elias M; Peretz A; Saliba W
    World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.